The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveReportar como inadecuado




The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Advances in Therapy

, Volume 33, Issue 11, pp 1896–1920

First Online: 27 September 2016Received: 01 August 2016DOI: 10.1007-s12325-016-0413-7

Cite this article as: San-Miguel, J.F., Einsele, H. & Moreau, P. Adv Ther 2016 33: 1896. doi:10.1007-s12325-016-0413-7

Abstract

Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway. In August 2015, the European Commission authorized panobinostat for use in combination with bortezomib and dexamethasone for the treatment of relapsed or relapsed and refractory multiple myeloma MM in patients who have received ≥2 prior regimens including bortezomib and an immunomodulatory drug. In January 2016, the National Institute for Health and Care Excellence recommended panobinostat for use in the same combination and patient population. The authorization and recommendation were based on results from the pivotal phase 3 PANORAMA 1 NCT01023308 clinical trial, which demonstrated an improvement in median progression-free survival of 7.8 months for the three-drug combination compared with placebo plus bortezomib and dexamethasone in this patient population. This review will discuss the current treatment landscape for relapsed-refractory MM, the mechanism of action of panobinostat, clinical data supporting the European authorization, concerns about safety and strategies for mitigating toxicity, and how panobinostat fits into the current MM landscape in Europe.

Funding : Editorial support, funded by Novartis Pharmaceuticals.

KeywordsMultiple myeloma Oncology Panobinostat Relapsed Relapsed and refractory Enhanced contentTo view enhanced content for this article go to http:-www.medengine.com-Redeem-A1E6F06042D48AA2.

Download fulltext PDF



Autor: Jesus F. San-Miguel - Hermann Einsele - Philippe Moreau

Fuente: https://link.springer.com/







Documentos relacionados